CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: bivalirudin
Accession: CHEBI:59173
browse the term
Definition: A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.
Synonyms: exact_synonym: D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine
related_synonym: (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-cyclohexylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-4-hydroxy-4-oxobutanoyl]amino]-3-cyclohexylpropanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid; Formula=C98H138N24O33; InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1; InChIKey=OIRCOABEOLEUMC-GEJPAHFPSA-N; SMILES=CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O; bivalirudina; bivalirudine; bivalirudinum
xref: Beilstein:12004535; CAS:128270-60-0; DrugBank:DB00006; Drug_Central:385
xref_mesh: MESH:C074619
xref: PMID:28844201; PMID:29086730; PMID:29276283; PMID:29342377; PMID:29345439; PMID:29345440; PMID:29345441; PMID:29345444; PMID:29350380; PMID:29377655; PMID:29461391; PMID:29477790; PMID:29544607; PMID:29563377; PMID:29600024; Patent:WO9102750
G
Crp
C-reactive protein
decreases expression
ISO
bivalirudin results in decreased expression of CRP protein
CTD
PMID:16118546
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
G
F2
coagulation factor II, thrombin
multiple interactions increases cleavage decreases activity
ISO
bivalirudin binds to and results in decreased activity of F2 protein; bivalirudin inhibits the reaction [F2 protein results in increased expression of SELP protein] F2 protein results in increased cleavage of bivalirudin bivalirudin results in decreased activity of F2 protein
CTD
PMID:1290488 PMID:8456428 PMID:15080313 PMID:15155122 PMID:16084352 PMID:16845256 PMID:17696810 PMID:18449412 PMID:19124943 PMID:19644995 More...
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
G
F2r
coagulation factor II (thrombin) receptor
decreases activity
ISO
bivalirudin results in decreased activity of F2R protein
CTD
PMID:19124943
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
G
F2rl3
F2R like thrombin or trypsin receptor 3
decreases activity
ISO
bivalirudin results in decreased activity of F2RL3 protein
CTD
PMID:19124943
NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472
G
Mpo
myeloperoxidase
decreases expression
ISO
bivalirudin results in decreased expression of MPO protein
CTD
PMID:18701766
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
G
P2ry12
purinergic receptor P2Y12
affects response to substance
ISO
P2RY12 affects the susceptibility to bivalirudin
CTD
PMID:14597584
NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361
G
Pdgfb
platelet derived growth factor subunit B
affects expression
EXP
bivalirudin affects the expression of PDGFB protein
CTD
PMID:10754393 PMID:11316950
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
G
Selp
selectin P
multiple interactions
ISO
bivalirudin inhibits the reaction [F2 protein results in increased expression of SELP protein]
CTD
PMID:16845256
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all